10X Genomics Hits Day High with 9.72% Surge, Outperforming Market

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has shown significant activity today, gaining 9.72% and reaching an intraday high of USD 28.17. This performance stands out against the S&P 500, which has only seen a 0.58% increase on the same day. Over the past week, 10X Genomics has surged by 13.41%, and its one-month performance reflects a robust 30.98% increase. Impressively, the stock has delivered a remarkable 215.91% return over the past year, significantly outperforming the S&P 500's 28.45% gain. Year-to-date, the stock has risen by 71.61%, further highlighting its strong market position. The company has reported positive results for five consecutive quarters, with an operating cash flow of USD 127.82 million, the highest recorded. Additionally, the debt-equity ratio stands at a low -56.3%, indicating a strong financial position. Despite its recent successes, the stock is considered risky compared to historical valuations, with institutional holdings at 100%, reflecting confidence from larger investors.